Valuation: FamiCord AG

Market Cap 49.16M 55.87M 45.7M 41.94M 78.74M 5.39B 80.02M 543M 212M 2.65B 210M 205M 9.16B P/E 2026 *
282x
P/E 2027 * 47x
Enterprise Value 57.16M 64.96M 53.14M 48.77M 91.55M 6.27B 93.04M 631M 246M 3.08B 244M 239M 10.65B EV / Sales 2026 *
0.67x
EV / Sales 2027 * 0.62x
Free-Float
26.82%
Yield 2026 *
-
Yield 2027 * -
1 day-66.71%
1 week+31.90%
Current month+14.29%
1 month+8.10%
3 months-8.62%
6 months-23.74%
Current year-32.35%
1 week 2.96
Extreme 2.96
4.19
1 month 2.89
Extreme 2.89
4.19
Current year 2.89
Extreme 2.89
6.1
1 year 2.89
Extreme 2.89
9.8
3 years 2.89
Extreme 2.89
9.8
5 years 2.89
Extreme 2.89
16.49
10 years 2.89
Extreme 2.89
17.04
Manager TitleAgeSince
Chief Executive Officer 54 21/03/2022
Director of Finance/CFO 53 31/07/2024
Chief Tech/Sci/R&D Officer - 28/02/2025
Director TitleAgeSince
Chairman 62 27/06/2017
Director/Board Member - 31/12/2016
Director/Board Member 54 30/11/2021
Change 5-day change 1-year change 3-year change Capi.($)
-66.71%+31.90% - - 55.97M
+0.80%+0.25%+83.39%+41.86% 137B
+1.51%+2.97%+11.92%+34.02% 84.78B
+2.22%+4.96%+3.79%+56.43% 28.09B
-0.02%+8.15%+32.55%+58.21% 25.15B
+1.32%0.00%-14.44%-27.43% 20.05B
+17.17%+19.64%+57.16%+203.29% 20.09B
+0.50%-0.65%+62.63%+130.60% 15.12B
-0.86%-6.71%+2.39%-7.05% 14.49B
+0.65%+2.44%-5.50%-10.95% 13.07B
Average -4.34%+3.45%+25.99%+53.22% 39.81B
Weighted average by Cap. +1.87%+2.65%+42.33%+47.30%

Financials

2026 *2027 *
Net sales 85M 96.6M 79.02M 72.52M 136M 9.33B 138M 939M 366M 4.57B 363M 355M 15.83B 88.4M 100M 82.18M 75.42M 142M 9.7B 144M 976M 381M 4.76B 377M 369M 16.46B
Net income 300K 341K 279K 256K 481K 32.92M 488K 3.31M 1.29M 16.14M 1.28M 1.25M 55.87M 1M 1.14M 930K 853K 1.6M 110M 1.63M 11.05M 4.31M 53.81M 4.27M 4.17M 186M
Net Debt 8M 9.09M 7.44M 6.83M 12.81M 878M 13.02M 88.37M 34.48M 430M 34.13M 33.4M 1.49B 6M 6.82M 5.58M 5.12M 9.61M 658M 9.77M 66.28M 25.86M 323M 25.6M 25.05M 1.12B
Logo FamiCord AG
FamiCord AG, formerly Vita 34 AG, is a Germany-based company operating in the medical technology sector and acts as a cell bank/stem bank. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected during the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. The cells also allow the growing of whole organs, such as the liver. On an average, one out of seven individuals, whose cells are sorted, receives autologous stem cell transplant by age of 70. The Company acts as a cord blood bank and is also engaged in research activities around regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.
Employees
723
Date Price Change Volume
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.820EUR
Average target price
6.500EUR
Spread / Average Target
+130.50%

Annual profits - Rate of surprise